News | Coronavirus (COVID-19) | April 08, 2020

No Evidence Supporting Discontinuing RAAS Inhibitors in COVID-19 Patients

ACE and ARBs provide benefit to cardiac patients and harm to COVID-19 patients remains unproven

ACE and ARBs provide benefit to cardiac patients and harm to COVID-19 patients remains unproven, NEJM

April 8, 2020 — There has been debate in the past month or so during the novel coronavirus (COVID-19) pandemic whether the renin-angiotensin-aldosterone system (RAAS) inhibitors, such as angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), should be stopped in COVID-19 patients. An article in the New England Journal of Medicine (NEJM) suggests these medications provide known benefits to patients who need them, while potential harms remain unproven.[1]

RAAS experts have provided a useful special report summarizing the evidence about the use of ACE inhibitors and ARBs, in patients with COVID-19. The data may provide context for the recommendations from several professional groups. The article suggests treatment with RAAS inhibitors should not be changed out of concerns that they might increase or decrease risk in patients with COVID-19, said Harlan M. Krumholz, M.D., director of the Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, who reviewed the article in NEJM Journal Watch.

SARS-CoV-2, the virus that causes COVID-19, enters cells by binding to ACE2 as a receptor. ACE2 counters RAAS activation, primarily by degrading angiotensin II to angiotensin-(1–7), reducing angiotensin II's effects on vasoconstriction, sodium retention, and fibrosis. Some preclinical studies indicated that RAAS inhibitors may increase the expression of ACE2, raising concerns that these medications could increase susceptibility to infection. Nevertheless, whether ACE inhibitors or ARBs harm patients with COVID-19 or, even, are protective against the disease remains unknown. 

However, withdrawing these therapies in patients for whom they are indicated could be expected to increase risks from patients' underlying conditions or from COVID-19 complications. The authors strongly endorse continuing RAAS inhibitors until better evidence suggests otherwise.

 

Related ACE and ARB COVID-19 Content:

COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues

AHA, ACC, HRS Caution Use of COVID-19 Therapies Hydroxychloroquine and Azithromycin in Cardiac Patients

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

VIDEO: What Cardiologists Need to Know about COVID-19 — Interview with Thomas Maddox, M.D.

Reference:

1. Vaduganathan M et al. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020 Mar 30; [e-pub]. https://doi.org/10.1056/NEJMsr2005760.

 

Related Content

News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
News | Cardiovascular Clinical Studies

June 1, 2022 — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced that its ...

Home June 01, 2022
Home
News | Cardiovascular Clinical Studies

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

Home May 31, 2022
Home
News | Cardiovascular Clinical Studies

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
News | Cardiovascular Clinical Studies

May 25, 2022 — Researchers from the group of Eva van Rooij used advanced sequencing technology to better understand the ...

Home May 25, 2022
Home
News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
Subscribe Now